Specimen Collection Cards Market Size, Share, Opportunities, And Trends By Type of Specimen (Blood, Saliva, Urine, Buccal Cells, Others), By Material (Cotton & Cellulose-based, Fiber-based, Others), By Product (Whatman 903, Ahlstrom 226, FTA, Others), Application (New Born Screening (NBS), Infectious Diseases Testing, Therapeutic Drug Monitoring, Forensics, Research, Wellbeing/Health Monitoring, Other Applications), And By Geography - Forecasts From 2025 To 2030

Specimen Collection Cards Market Size:

The specimen collection card market is projected to rise, achieving a 5.50% CAGR, to USD 789.853 million in 2030 from USD 604.468 million in 2025.

Specimen Collection Cards Market Key Highlights:

• Specimen collection cards are facilitating efficient bio-sample collection and transportation.
• Cards are preserving DNA integrity for reliable elution at ambient temperatures.
• Forensic science centers are utilizing cards for secure biological evidence preservation.
• Government investments are enhancing diagnostic capabilities, boosting card demand.

Specimen collection cards are purposefully crafted to facilitate the collection and transportation of various bio-samples, such as blood, saliva, buccal cells, and urine. Also, they excel in preserving DNA integrity, ensuring its swift elution even after extended periods of storage at ambient temperatures. The applications of specimen card collection encompass a wide range of areas, including Newborn Screening (NBS), infectious diseases testing, therapeutic drug monitoring, forensics, research, well-being/health monitoring, and other diverse applications.

Specimen Collection Cards Market Drivers:

• Improved pathology bolsters the specimen collection cards market growth.

Specimen collection cards are extensively used in medical laboratories and pathology by scientists due to their convenience and effectiveness in preserving various biological samples like blood, saliva, buccal cells, and urine. These cards enable safe and efficient sample collection, transportation, and storage, making them an indispensable tool for diagnostic testing purposes. The increasing demand for specimen collection cards can be attributed to the growing number of scientists engaged in diverse fields of research, who recognize the value of these cards for non-invasive sampling, and reliable DNA elution. For instance, In 2020, the number of medical and pathology scientists in Canada surged to 19,757, marking a notable 6.8% increase compared to the previous year.

• Improved forensic science centres' establishments drive the specimen collection card market.

Specimen collection cards are utilized in forensic science centres for their crucial role in securely preserving and transporting biological evidence collected from crime scenes, victims, or suspects. These cards enable easy, non-invasive sampling of blood, saliva, and other bodily fluids, ensuring the integrity of DNA and other biomarkers for accurate analysis and evidence documentation. Forensic science centres are experiencing rapid growth due to increasing demand for scientific advancements in criminal investigations. According to the Ministry of Home Affairs, in May 2023, the Government of India established its 10th National Forensic Science University (NFSU) centre in Guwahati, also making it the world's 11th centre.

• Government initiatives and investments drive the specimen collection cards market.

The specimen collection cards industry is experiencing significant growth driven by government initiatives and investments aimed at bolstering diagnostic centres with a focus on improving healthcare services and enhancing early disease detection. Specimen collection cards play a crucial role in this context, as they enable efficient and reliable sample collection, and ensure the accuracy of diagnostic tests. For instance, in November 2021, the UK government allocated approximately $337 million in funding to the NHS, dedicated to enhancing the technological infrastructure of its diagnostic services. The primary objective of this investment was to streamline the entire process of ordering, performing, and reviewing medical tests within the NHS (National Health Service).

• Alternatives availability restrains the specimen collection cards market growth.

The presence of stiff competition from alternative sample collection methods, including liquid-based collection systems and automated sampling devices is contracting the specimen collection cards industry growth. These alternative methods offer diverse advantages, such as enhanced ease of use, higher throughput, and compatibility with specific analytes, leading to potential shifts in preferences within the medical and research communities, which could in turn influence the overall demand for specimen collection cards.

Specimen Collection Cards Market Geographical Outlook:

• Asia-Pacific is expected to dominate the market.

Asia-Pacific will hold a significant share of the specimen collection card market due to a substantial increase in the number of pathology scientists, contributing to a surge in demand for reliable and efficient sample collection methods. For instance, according to the World Health Organization, in 2020, the number of medical and pathology scientists in India surged to 635,500, marking a remarkable 65% increase from the figures recorded in 2018. Additionally, governments in the region have undertaken significant investments to boost diagnostic centres’ capabilities and enhance healthcare infrastructure For instance, in June 2020, Chinese authorities launched an initiative to collect blood samples of males 700 million males including men and boys across the country to create a genetic database that would provide the government with a sophisticated tool for their advancing high-tech surveillance capabilities.

Specimen Collection Cards Market Key Developments:

• February 2023: Capitainer AB introduced an innovative self-sampling product to the market, boasting the capability to collect five times more blood than its previous version. This advancement allows for a wider range of analyses and testing options. Additionally, the new product has been designed to be more user-friendly, simplifying the implementation process for laboratories. Its improved features hold the potential to revolutionize blood sample collection and analysis, offering enhanced efficiency and flexibility in diagnostic and research.
• July 2022: Rhinostics introduced the revolutionary VERIstic, a groundbreaking collection device that redefines small-volume blood collection. It seamlessly combines the proven method of capillary blood collection with an integrated, automation-ready cap, streamlining the process and offering significant benefits for time, cost, and workflow efficiency in laboratories. For patients and clinicians alike, the collection procedure is now rapid, simple, and comfortable, enhancing the overall experience and facilitating a hands-free workflow from sample collection to laboratory analysis.
• May 2022: Abson Diagnostics and Becton, Dickinson and Company (BD) have further strengthened their strategic collaboration, aiming to spearhead innovation in blood sample collection, with a specific focus on exploring new care settings. The expanded partnership aims to empower patients by allowing them to conveniently collect blood samples at home for diagnostic testing, offering greater accessibility and ease of healthcare services. This advancement promises to revolutionize the way diagnostic testing is conducted, bringing the benefits of home-based blood sample collection to patients and healthcare providers.

Specimen Collection Cards Market Company Products:

• EasiCollect Plus: QIAGEN introduces EasiCollect Plus, an advanced buccal sample collection device that boasts an integrated and closable design, ensuring both consistent and reliable sample transfer while providing secure transportation. This advanced solution offers a user-friendly and seamless approach to collecting buccal samples, guaranteeing their integrity during transportation, and significantly improving the precision and efficiency of sample analysis across a range of applications.

List of Top Specimen Collection Cards Companies:

• QIAGEN
• PerkinElmer Inc.
• Euroimmun
• Eastern Business Forms, Inc.
• Ahlstrom

Specimen Collection Cards Market Scope:

Report Metric	Details
Specimen Collection Cards Market Size in 2025	USD 604.468 million
Specimen Collection Cards Market Size in 2030	USD 789.853 million
Growth Rate	CAGR of 5.50%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Million
Segmentation	Type of Specimen Material Product Application Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in Specimen Collection Cards Market	Ahlstrom ARCHIMED Life Science GmbH GenTegra LLC FortiusBio CENTOGENE N.V.
Customization Scope	Free report customization with purchase

Segmentation

• By Type of Specimen
  • Blood
  • Saliva
  • Urine
  • Buccal Cells
  • Others
• By Material
  • Cotton & Cellulose-based
  • Fiber-based
  • Others
• By Product
  • Whatman 903
  • Ahlstrom 226
  • FTA
  • Others
• By Application
  • New Born Screening (NBS)
  • Infectious Diseases Testing
  • Therapeutic Drug Monitoring
  • Forensics
  • Research
  • Wellbeing/Health Monitoring
  • Other Applications
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

---

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. SPECIMEN COLLECTION CARDS MARKET, BY TYPE OF SPECIMEN

5.1. Introduction

5.2. Blood

5.3. Saliva

5.4. Urine

5.5. Buccal Cells

5.6. Others

6. SPECIMEN COLLECTION CARDS MARKET, BY MATERIAL

6.1. Introduction

6.2. Cotton & Cellulose-based

6.3. Fiber-based

6.4. Others

7. SPECIMEN COLLECTION CARDS MARKET, BY PRODUCT

7.1. Introduction

7.2. Whatman 903

7.3. Ahlstrom 226

7.4. FTA

7.5. Others

8. SPECIMEN COLLECTION CARDS MARKET, BY APPLICATION

8.1. Introduction

8.2. New Born Screening (NBS)

8.3. Infectious Diseases Testing

8.4. Therapeutic Drug Monitoring

8.5. Forensics

8.6. Research

8.7. Wellbeing/Health Monitoring

8.8. Other Applications

9. SPECIMEN COLLECTION CARDS MARKET, BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. United States

9.2.2. Canada

9.2.3. Mexico

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. United Kingdom

9.4.2. Germany

9.4.3. France

9.4.4. Spain

9.4.5. Others

9.5. The Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. UAE

9.5.3. Israel

9.5.4. Others

9.6. Asia Pacific

9.6.1. Japan

9.6.2. China

9.6.3. India

9.6.4. South Korea

9.6.5. Indonesia

9.6.6. Thailand

9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

11.1. QIAGEN

11.2. PerkinElmer Inc.

11.3. Euroimmun

11.4. Eastern Business Forms, Inc.

11.5. Ahlstrom

11.6. ARCHIMED Life Science GmbH

11.7. GenTegra LLC

11.8. FortiusBio

11.9. CENTOGENE N.V.

QIAGEN

PerkinElmer Inc.

Euroimmun

Eastern Business Forms, Inc.

Ahlstrom

ARCHIMED Life Science GmbH

GenTegra LLC

FortiusBio

CENTOGENE N.V.